
==== Front
Indian J Psychiatry
Indian J Psychiatry
IJPsy
Indian J Psychiatry
Indian Journal of Psychiatry
0019-5545
1998-3794
Wolters Kluwer - Medknow India

IJPsy-66-630
10.4103/indianjpsychiatry.indianjpsychiatry_79_24
Original Article
Dual diagnosis and their care pathways for help-seeking: A multicenter study from India
Ghosh Abhishek
Mukherjee Diptadhi 1
Khanra Sourav 2
Prasad Sambhu 3
Mahintamani Tathagata 1
Basu Aniruddha 4
Padhy Susanta 5
Suthar Navratan 6
Somani Aditya 7
Arya Sidharth 8
Das Basudeb 2
Kumar Pankaj 3
Rina Kumari 4
Haokip Hoineiting Rebecca 4
Guin Aparajita 4
Mishra Shree 5
Nebhinani Naresh 6
Singh Lokesh K. 7
Gupta Rajiv 8
Kaur Ramandeep 9
Basu Debasish
Department of Psychiatry, Drug De-addiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India
1 Department of Addiction Medicine, Lokopriya Gopinath Bordoloi Regional Institute of Mental Health, Tezpur, Assam, India
2 Department of Psychiatry, Central Institute of Psychiatry, Ranchi, Jharkhand, India
3 Department of Psychiatry, All India Institute of Medical Sciences, Patna, Bihar, India
4 Department of Psychiatry, All India Institute of Medical Sciences, Kalyani, West Bengal, India
5 Department of Psychiatry, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India
6 Department of Psychiatry, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India
7 Department of Psychiatry, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
8 Department of Psychiatry, Institute of Mental Health, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India
9 Department of Psychiatry, Government Medical College, Chandigarh, India
Address for correspondence: Dr. Abhishek Ghosh, Department of Psychiatry, Drug De-addiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India. E-mail: ghoshabhishek12@gmail.com
7 2024
17 7 2024
66 7 630640
23 1 2024
24 6 2024
25 6 2024
Copyright: © 2024 Indian Journal of Psychiatry
2024
https://creativecommons.org/licenses/by-nc-sa/4.0/ This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Background:

Understanding pathways to dual diagnosis (DD) care will help organize DD services and facilitate training and referral across healthcare sectors.

Aim:

The aim of our study was to characterize the stepwise healthcare and other contacts among patients with DD, compare the characteristics of the first contact persons with common mental disorder (CMD) versus severe mental illness (SMI), and estimate the likelihood of receiving appropriate DD treatment across levels of contacts.

Methods:

This cross-sectional, descriptive study in eight Indian centers included newly enrolled patients with DD between April 2022 and February 2023. The research spans varied geographic regions, tapping into regional variations in disease burden, health practices, and demographics. The study categorized healthcare contacts by using the WHO Pathways Encounter Form.

Results:

The sample (n = 589) had a median age of 32 years, mostly males (96%). Alcohol was the most common substance; SMI (50.8%) and CMD were equally represented. Traditional healers were a common first contact choice (18.5%); however, integrated DD care dominated subsequent contacts. Assistance likelihood increased from the first to the second contact (23.1% to 62.1%) but declined in subsequent contacts, except for a significant rise in the fifth contact (97.4%). In the initial contact, patients with CMD sought help from public-general hospitals and private practitioners for SUD symptoms; individuals with SMI leaned on relatives and sought out traditional healers for psychiatric symptoms.

Conclusion:

Recognizing the cultural nuances, advocating for integrated care, and addressing systemic challenges pave the way to bridge the gap in DD treatment.

Dual diagnosis
help seeking
India
multicentric
substance use disorder
==== Body
pmcINTRODUCTION

Dual diagnosis (DD) is defined as the concurrent presence of substance use disorder (SUD) and other psychiatric disorders. Approximately 50%–60% of those with either SUD or any mental illness have DD.[1] Studies from low- and middle-income countries (LMICs) demonstrated a similar high co-occurrence. For instance, a study from Nigeria showed that two-thirds of patients with SUD had co-occurring schizophrenia spectrum disorder.[2] Data on the prevalence of DD in India lacks any national estimate.[3] Different estimates across centers have suggested a prevalence ranging from 11% to 40%.[456789]

Persons with DD have higher morbidity and mortality. There is a higher incidence of homelessness, social exclusion, and unemployment.[10] A recent retrospective cohort study from India in patients hospitalized for AUD showed that severe mental illness (SMI) doubled the odds of hospital readmission over 5 years.[4] Individuals with DD are more likely to relapse to substance misuse and psychiatric symptoms, contributing to the poor course and outcome of both conditions.[1112] Treating individuals with DD is challenging due to complex clinical and psychosocial needs. The reluctance stems from fear of drug interactions, limited training, and compartmentalized services, leading to underreporting and exclusion.[13] Although different models of DD care are documented in high-income countries,[141516] these are resource-intensive and thus less sustainable in LMICs.[17]

Nevertheless, integrated DD care might be more favorable in terms of service users’ experience and treatment outcomes.[16] A review from India[3] lamented the lack of provision of a uniform, evidence-based system of DD care, even in tertiary care settings.

In India, the treatment gaps for mental illness and SUD are between 75% and 85%.[1819] A serious lack in the number of trained mental health professionals, poor coverage of mental healthcare at district-level hospitals, and limited awareness and high stigma among service providers and users contribute to the treatment gap.[18] Despite four decades of a national mental health program, the treatment gap remains high for individuals with mental illness. The gap is likely greater for those with DD due to the lack of a specific care policy.

Pathways to care, which map sequential help-seeking behavior and document the care received during those encounters, might help understand the DD care needs.[20] Pathways of help-seeking are the critical link between the onset of problems and the provision of health care.[21] Therefore, DD care pathways may also help clinical decision-making and effective service delivery. A study of help-seeking pathways assumes more importance in India because mental healthcare is delivered by various service organizations.[18] In addition to public healthcare, it has a dominant private for-profit healthcare system. The accessibility and availability of mental healthcare and the type of healthcare organizations also differ across states.[18] Hence, a better understanding of pathways to DD care, preferably from multiple sites across the country, will help organize DD services and facilitate training and referral.

Moreover, no previous studies from India or elsewhere have examined care pathways for persons with DD. However, studies among patients with mental illness showed different help-seeking pathways from anxiety and depressive disorders versus psychosis. The former group seeks help from primary care, whereas the latter prefers mental healthcare services.[22] Previous reviews showed a different care-seeking pattern in LMICs versus high-income countries.[23]

The aim of our multisite study from an LMIC was to 1) characterize the step-wise healthcare and other contacts among patients with DD, 2) compare the characteristics of the first contacts persons with common mental disorder (CMD) versus SMI, and 3) estimate likelihood of receiving appropriate DD treatment.

MATERIALS AND METHODS

Study design and setting

This cross-sectional study spanned nine Indian centers, covering northern (n = 2), western (n = 1), central (n = 2), eastern (n = 3), and north-eastern (n = 1) states and union territories. The number of participants from the northern, western, eastern, central, and northeast centers was 54, 15, 279, 226, and 15, respectively. Please see Supplementary Figure 1 for further details. All study centers provide integrated DD care; however, these are structurally located within the tertiary care SUD service (n = 4) or mental health service (n = 4). Teams in tertiary care SUD or mental health services provided integrated DD care. State-wise analysis revealed mental disorder burden variations, potentially linked to sociodemographic index (SDI) differences (India State-Level Disease Burden Initiative Mental Disorders Collaborators, 2020).[24] Substance use patterns also varied regionally (Ambekar et al., 2019).[19] Opioid prevalence was high in the north and northeast, while the east and central regions had more alcohol and cannabis use. Finally, mental health service organizations and coverage differ in these states.[18] Ethics approval was obtained from each institute, and data collection occurred between April 2022 and February 2023, with varying study periods due to approval and administrative differences.

Participants

Consecutive newly enrolled patients over 18 years seeking treatment from any of the study sites during the prespecified period were eligible for the study. All participants had a substance dependence diagnosis and a diagnosis of other mental disorders per the International Classification of Disease 10th version.[25] Patients with only tobacco use disorder and not willing to provide informed consent were excluded. Qualified psychiatrists made the diagnosis. This study was a subgroup analysis of a larger study on patients with SUDs.

Variables

We defined eight healthcare contact levels based on structural, functional, and cost factors. Mental health and addiction services, with or without integrated DD care, were classified, along with traditional informal care and private-for-profit healthcare. Other public healthcare categories are outlined in Table S1. Demographic and clinical variables were collected, including age, sex, socioeconomic status, substance use details, psychiatric and medical comorbidities, and treatment initiation factors. Symptoms leading to healthcare contact were categorized into substance use disorder (SUD), mental health, both, or other symptoms. Treatment types were divided into five categories, with pharmacological treatment further categorized for SUD, mental illness, or both. Rural-urban status was determined using 2011 census data. Comorbid medical illnesses were recorded from health records. Mental illnesses were classified as CMD (anxiety, depression, obsessive-compulsive disorder, dysthymia) and SMI (psychosis, bipolar disorder, recurrent depression). The rationale for this distinction is the different severity, presentation, course, outcome, and treatment needs of these two patient groups.[22] These differences might contribute to different help-seeking behavior. We compared the healthcare contact characteristics of those with CMD versus SMI.

Table S1: Glossary of terms and description of different treatment services

Public-funded addiction services or de-addiction centers (DACs)	Government-funded addiction clinics/opioid substitute centers/buprenorphine substitution centers/detoxification centers. Psychiatrists and medical officers run these centers with experience in addiction treatment. However, integrated care is not expected in these centers.	
Specialized addiction services with integrated care (SAS)	Centers are funded by the government and run by psychiatrists/addiction psychiatrists. In our study, these represent tertiary care treatment facilities such as the Center for Addiction Psychiatry of CIP Ranchi, DTC PGIMER Chandigarh, Department of Addiction Medicine, LGBRIMH, and PGIMS Rohtak. Integrated treatment is available in these centers.	
Mental health services with integrated addiction services (MHSI)	These centers are funded by the government and run by psychiatrists (at times addiction psychiatrists). In our study, it includes the psychiatry department of tertiary care treatment facilities such as AIIMS Patna, AIIMS Jodhpur, and AIIMS Bhubaneswar. Integrated treatment is available in these centers. Integrated treatment is available in these centers.	
Mental health services (MHS)	Government-funded psychiatric hospital. These centers are run by psychiatrists and medical officers with OPD and IPD facilities. Often, these centers lack specialist addiction services. So, integrated care is not expected in these centers.	
Religious/Native practices (RNP)	Religious and native healing practices encompass a wide range of spiritual approaches. These practices are deeply rooted in the beliefs and traditions of various cultures and often involve rituals, ceremonies, and natural remedies. Some examples include faith healing, shamanic healing, AYUSH, and crystal healing. These practices may involve prayer, herbal remedies, rituals, etc.	
General Hospital (GH)/Emergency services (ES)/Primary health centers (PHC)	Are government-funded Primary and secondary level care. General hospitals sometimes have in-house psychiatrists and run Psychiatry OPD. Whereas Primary Health Centers, emergency services of GH lacks specialist psychiatrist/addiction specialist.	
Private medical facilities (PvtM)	Are run by private enterprises and involve general physicians and general surgeons but not psychiatrists.	
Private psychiatric/DAC (PvtP)	Non-government psychiatric clinic/psychiatric nursing home/addiction clinics/opioid substitute centers/detoxification centers. These centers are run by psychiatrists and medical officers (with or without experience in addiction treatment). Integrated care may or may not be available in these centers.	

We created a proxy variable named “likelihood of being helped.” Those who contacted integrated DD care were considered as “being helped.”[16]

Data sources and measurement

The Pathway Study Encounter Form by the WHO collaborative study[26] was used in our study. It is a culture-neutral questionnaire designed to systematically assess sources of care used by patients before consulting a mental health professional. It has been used for Indian patients with SUDs.[627] We have included minor changes made by Balhara et al.[6] and Bhad et al.[27] into the original form to make it more appropriate for our study sample.

Trained mental healthcare professionals collected information.

All data were collected in real time on a Google form. DM, TM, and AG periodically checked for incomplete and incorrect/invalid entries.

Bias

Our study might have a selection bias because patients seeking treatment in the tertiary care integrated DD care might differ from those seeking treatment from other healthcare or informal sectors and patients with DD living in the community. Our study can only draw inferences for the former group of persons with DD. By consecutive sampling, we aimed to reduce the selection bias; however, the systematic difference in the patients’ characteristics might still need to be addressed. Even random sampling would not have addressed this concern. We enquired about the history of sequential healthcare contacts, which might be subjected to recall bias.

Study size

This was a descriptive, exploratory study, and we performed no power calculation.

Statistical analysis

Descriptive statistics was expressed as frequencies and percentages for categorical variables and mean, median, and standard deviation/interquartile range for continuous variables. Group comparisons of categorical variables were performed using the Chi-square and Fisher’s exact tests. Independent t-test (two groups) or its non-parametric equivalent, the Mann-Whitney U test, made similar comparisons for the continuous variables. The Chi-square test compared the “likelihood of being helped” between healthcare contacts. The significance level was kept at P < 0.05.

RESULTS

A total of 1920 patients were approached. We excluded 303 patients for various reasons (time constraints cited by patients = 113, did not consent = 38, only tobacco use disorder = 19, had severe withdrawal symptoms = 85, had symptoms of intoxication = 48). We also excluded 1617 with only SUD diagnosis from the analysis for this work. Pathways to care for only the SUD population have been published separately.[28] There are several reasons for creating separate reports for SUD and DD. First, the pathways to seeking care are notably different between these groups. Merging them would increase heterogeneity and make our findings harder to interpret. Second, for patients with DD, the definition of healthcare contacts needs adjustment. For instance, mental health facilities at the tertiary level with integrated SUD treatment, either functionally or structurally, should be classified as providing integrated care for DD. This integration is less relevant for individuals with only SUD. Third, distinct care pathways carry different clinical and policy implications for patients with SUD versus those with DD.

Hence, 599 patients with DD were included in this study; however, the first contact information was available for 589 patients, and the final analysis was done for these 589 patients.

Sociodemographic and clinical characteristics of the sample

Study participants, with a median age of 32 (IQR: 15–77) years, were predominantly male (96%) with intermediate education (median: 12 years; IQR: 8–15 years). Most were married (60%) and employed (78%). Over half were non-indigenous (57.4%), rural dwellers (61.6%), and from nuclear families (52.8%). Alcohol dependence was prevalent (68.4%), followed by tobacco and cannabis (61.5% and 51.8%). Opioid dependence was reported by 25.6%. Psychotic spectrum disorders (39.4%) were common, with depressive, anxiety, and bipolar spectrum disorders accounting for 26.2%, 22.2%, and 11.2%, respectively. SMI constituted 50.8%, while CMD made up 49.2%. Furthermore, 16.8% reported comorbid medical illnesses. For further details, please refer to Table 1.

Table 1: Details of sociodemographic and clinical characteristics of the sample (n=588)

Variable	Median (IQR)/n (%)	
Age in years (n=588)	32.0 (Range: 25–41)	
Years of education (n=589)	12.0 (Range: 8–15)	
Gender (n=589)		
    Male	565 (95.9)	
    Female	24 (4.1)	
Indigenous population (n=589)		
    No	338 (57.4)	
    Yes	223 (37.9)	
    Not known	30 (4.8)	
Marital status (n=589)		
    Married	353 (59.9)	
    Separated	23 (3.9)	
    Single	208 (35.3)	
    Widowed	5 (0.8)	
Employment status (n=589)		
    Employed	459 (77.9)	
    Unemployed	130 (22.1)	
Locality (n=589)		
    Rural	363 (61.6)	
    Urban	219 (37.2)	
    Unknown	7 (1.2)	
Religion (n=589)		
    Hindu	483 (82.0)	
    Islam	69 (11.7)	
    Sikh	16 (2.7)	
    Others/data absent	21 (3.6)	
Family type (n=589)		
    Nuclear	311 (52.8)	
    Joint/Extended	269 (45.7)	
    Others/Not known	9 (1.5)	
Socioeconomic status (Modified Kuppuswamy) (n=520)		
    Upper	21 (4.0)	
    Upper middle	238 (45.8)	
    Lower middle	121 (23.3)	
    Upper lower	127 (24.4)	
    Lower	13 (2.5)	
    Duration of substance use (months) (n=583)	84 (48–180)	
    Duration of substance dependence (months) (n=575)	46 (25–95)	
    Duration of mental health symptoms (months) (n=575)	28 (12–48)	
Primary substance (n=589)		
    Alcohol	403 (68.4)	
    Cannabis	77 (13.1)	
    Opioids	67 (11.4)	
    Tobacco	26 (4.4)	
    Sedatives	14 (2.3)	
    Others	2 (0.4)	
Profile of active dependence (n=589)		
    Alcohol dependence	399 (67.7)	
    Tobacco dependence	362 (61.5)	
    Cannabis dependence	305 (51.8)	
    Opioids dependence	151 (25.6)	
    Sedative dependence	38 (6.5)	
Emergency reception visit		
    Yes	55 (9.3)	
    No	135 (22.9)	
    Not known	399 (67.7)	
Conflict with law		
    Yes	16 (2.7)	
    No/Not known	573 (97.3)	
First symptom		
    Compulsion	336 (57.0)	
    Withdrawal	123 (20.9)	
    Tolerance	39 (6.6)	
    Loss of control	30 (5.1)	
    Use despite harm	21 (3.6)	
    Neglect of pleasurable activities	9 (1.5)	
    Craving	4 (0.7)	
Psychiatric Illness		
    Psychotic Spectrum (F1X.5 & F20–F29)	235 (39.9)	
    Depressive Spectrum (F32–F39)	155 (26.3)	
    Anxiety Spectrum (F40–F49)	135 (22.9)	
    Bipolar Spectrum (F30–F31)	64 (10.9)	
Comorbid Medical illness		
    Present	99 (16.8)	
    Absent	170 (28.9)	
    Absent/Not known	320 (54.3)	

Details of the pathways to care for DD disorders

1st contact details

Among 589 first-contact participants, 18.5% chose religious/native practices, followed by specialized addiction services with integrated care (17.3%) and govt general hospital/emergency services (15%). Private medical and private psychiatric services each attracted 8.8% of patients. Mental health services and primary health care were contacted by 7.0% and 6.6% of patients, respectively. Initiators were mainly relatives (64.7%), patients themselves (25.3%), and psychiatric symptoms-triggered contact (31.2%). Addiction-related symptoms prompted 21.9%, and a combination led to 25.1% of cases. Pharmacotherapy was received by 57%, and 7.6% underwent a combination of medication and psychosocial interventions.

2nd contact details

The median time between first and second contacts was 14 months (IQR: 12–38 months). Among 430 patients with a second contact, 48.6% sought specialized addiction services, followed by government general hospitals/emergency services (14.4%) and mental health services with integrated addiction services (13.5%). Relatives initiated 45.1% of contacts, patients 30.9%, and medical practitioners 12.5%. Psychiatric symptoms prompted 2/5th of contacts, while addiction-related and combined symptoms each accounted for 1/5th. Most patients (60%) received pharmacotherapy, and 30% had a combination of pharmacological and psychosocial interventions.

3rd contact details

The median time between second and third contacts was 12 months (IQR: 1.75–35 months). Among 158 patients, 43.7% contacted specialized addiction services, 25.9% general hospitals/emergency services, and 5.1% mental health services with integrated services. Relatives initiated 39.2% of contacts, patients 30.4%, and healthcare providers 29.1%. Over one-fifth sought help for unrelated medical/surgical symptoms. Nearly 70% received pharmacological treatment exclusively, and 23% had a combination of medication and psychosocial interventions.

4th contact details

The time between the third and fourth contact was 4 months (IQR: 1.25–28.5 months). Among 79 patients, 40.5% visited specialized addiction services, 8.9% mental health services, and 27.8% government general hospitals. Mental healthcare specialists initiated 27.8% of contacts, patients 24.1%, medical practitioners 24.1%, and relatives 22.5%. Addiction-related reasons prompted 44.3% of contacts. Pharmacological treatment alone was received by 58%, and 37% had a combination of pharmacological and psychological treatment.

5th contact details

The median duration between the fourth and fifth contacts was 1 month (IQR: 1–5 months). Among 39 patients with a fifth contact, almost all sought treatment from specialized addiction services (SAS). Patients, relatives, and healthcare providers initiated the contact in about one-third of cases, with significant involvement from mental healthcare specialists and medical practitioners. Nearly all patients received medical care, and over two-thirds also had additional psychosocial intervention. For further details, please refer to Table 2.

Table 2: Details related to stepwise treatment contact (1st to 5th contact)

Variable	Number (%) (Range)/n (%)	
First contact (n=589)		
    Religious/Native Practices (RNP)	109 (18.5)	
    Specialized addiction services with integrated care (SAS)	102 (17.3)	
    Govt general hospital/Emergency service	86 (14.6)	
    Private psychiatrist/Private DAC	52 (8.8)	
    Private Medical practitioner (PvtM)	52 (8.8)	
    Mental health service	41 (7.0)	
    PHC	39 (6.6)	
    Mental health services with integrated addiction services (MHSI)	34 (5.8)	
    Community health worker/Pharmacist/Social worker/Self-medication/Others	28 (4.7)	
    Public-funded addiction services or de-addiction center (DAC)	26 (4.4)	
Who initiated the first contact?		
    Relatives/friends	381 (64.7)	
    Patient self	149 (25.3)	
    Workmate/employers	43 (4.3)	
    Medical practitioners	27 (4.6)	
    Not available	13 (2.2)	
    Others (Neighbors, police)	5 (0.9)	
What symptoms led to the first contact?		
    Psychiatric symptoms-related	184 (31.2)	
    Addiction-related	129 (21.9)	
    Mixed	148 (25.1)	
    Others (Medical, surgical, unrelated)	44 (7.5)	
    Not available	84 (14.3)	
Nature of treatment at first contact (n=589)		
    Pharmacological only	334 (56.7)	
    Psychosocial only	23 (3.9)	
    Religious/Native	109 (18.5)	
    Pharmacological and Psychosocial	45 (7.6)	
    Referral	16 (2.7)	
    Record NA	62 (10.5)	
Pharmacological Break-up (n=158)		
    Addiction-related	81 (51.3)	
    Psychiatry-related	47 (29.7)	
    Both	30 (19.0)	
Second contact (n=430)		
Who was seen?
Who initiated the third contact?		
    Specialized addiction services with integrated care (SAS)	209 (48.6)	
    Govt general hospital/Emergency service	62 (14.4)	
    Mental health services with integrated addiction services (MHSI)	58 (13.5)	
    Private practitioner (medical)	31 (7.2)	
    Private psychiatrist/Private DAC	21 (4.9)	
    Mental health service	20 (4.6)	
    Religious/Native practices (RNP)	10 (2.3)	
    Public-funded addiction services (DAC)	6 (1.4)	
    Others (self-medication/community health work/PHC/ES)	13 (3.0)	
Who initiated the first contact?		
    Relatives/friends	261 (60.7)	
    Patient self	89 (20.7)	
    Medical practitioners	38 (8.3)	
    Mental healthcare specialists	18 (4.2)	
    Others (Neighbors/police/workmates/employers)	11 (2.5)	
    Not available	13 (2.9)	
What symptoms led to the second contact?		
    Psychiatric symptoms-related	167 (38.8)	
    Addiction-related	92 (21.4)	
    Mixed	84 (19.5)	
    Others (Medical, surgical, unrelated)	44 (10.2)	
    Not available	43 (10.0)	
Nature of treatment at second contact		
    Pharmacological only	258 (60.0)	
    Psychosocial only	3 (0.7)	
    Pharmacological and psychosocial	129 (30.0)	
    Referral	11 (2.5)	
    Traditional and others	11 (2.5)	
    Record NA	18 (4.2)	
Pharmacological Break-up (n=191)		
    Addiction-related	98 (51.3)	
    Psychiatry-related	64 (33.5)	
    Both	29 (15.2)	
Third contact (n=158)		
Who was seen?		
    Specialized addiction services with integrated care (SAS)	69 (43.7)	
    Govt general hospital/Emergency service	41 (25.9)	
    Mental health services with integrated services (MHSI)	8 (5.1)	
    Public-funded addiction services (DAC)	7 (4.4)	
    Mental health service	7 (4.4)	
    Others (Traditional, private practitioner, psychiatry, etc.)	25 (15.8)	
Who initiated the third contact?		
    Relatives/friends	62 (39.2)	
    Patient self	48 (30.4)	
    Medical practitioners	27 (17.1)	
    Mental healthcare specialists	19 (12.0)	
    Others	2 (1.3)	
What symptoms led to the third contact?		
    Addiction-related	60 (38.0)	
    Psychiatric symptoms-related	40 (25.3)	
    Mixed	21 (13.3)	
    Others (Medical, surgical, unrelated)	33 (20.9)	
    Not available	4 (2.5)	
Nature of treatment at third contact		
    Pharmacological only	110 (69.6)	
    Psychosocial only	3 (1.9)	
    Pharmacological and Psychosocial (both)	37 (23.4)	
    Traditional and others	7 (4.4)	
    Record NA	1 (0.6)	
Pharmacological		
    Addiction-related only	18 (32.1)	
Break-up (n=56)		
    Psychiatry-related only	14 (25.0)	
    Both	24 (42.9)	
Fourth contact (n=79)		
Who was seen?		
    Specialized addiction services with integrated care (SAS)	32 (40.5)	
    Govt general hospital/Emergency service	22 (27.8)	
    Addiction services	5 (6.3)	
    Mental health service	6 (7.6)	
    Mental health services with integrated services (MHSI)	7 (8.9)	
    Others	7 (9.2)	
Who initiated the fourth contact?		
    Mental healthcare specialists	22 (27.8)	
    Patient self	19 (24.1)	
    Medical practitioners	19 (24.1)	
    Relatives	18 (22.8)	
    Neighbor	1	
What symptoms led to the fourth contact?		
    Addiction-related	35 (44.3)	
    Psychiatric symptoms-related	17 (21.5)	
    Mixed	11 (13.9)	
    Others (Medical, surgical, unrelated)	14 (17.7)	
    Not available	2 (2.5)	
Nature of treatment at fourth contact		
    Pharmacological only	46 (58.2)	
    Psychosocial only	1 (1.3)	
    Pharmacological and psychosocial both	29 (36.7)	
    Record NA	1	
Fifth contact (n=39)		
Who was seen?		
    Specialized addiction services with integrated care (SAS)	35 (89.7)	
    Others	4	
Who initiated the fifth contact?		
    Mental healthcare specialists	19 (48.7)	
    Medical practitioners	9 (23.1)	
    Others	11 (28.2)	
What symptoms led to the fifth contact?		
    Addiction-related only	29 (74.4)	
    Psychiatric symptoms-related only	2	
    Mixed	8	
Nature of treatment at fifth contact		
Pharmacological only	11 (28.2)	
Psychosocial only	1 (2.6)	
Pharmacological and psychosocial (both)	27 (69.2)	

The likelihood of receiving appropriate assistance in subsequent contacts

Receiving integrated services (SAS or MHSI) significantly increased from the first (23.1%) to the second contact (62.1%) (χ2 158.15, P < 0.00001). However, assistance declined between the 2nd and 3rd contacts (49.4%) (χ2 7.717, P = 0.005). The 3rd and 4th contacts showed consistent assistance (49.4% vs. 49.4%, χ2 0, P = 1). Significantly higher help rates were observed in the 5th contact compared to the 4th (97.4% vs. 49.4%, χ2 26.6, P < 0.00001). For details, see Supplementary Table S2.

Table S2: The likelihood of appropriate assistance in subsequent contacts

	Reached Integrated care	Did not reach Integrated care	Likelihood of reaching integrated care	Chi-square, P	
First Contact	136	453	23.1%	χ2=158.15, P<0.00001	
Second Contact	267	163	62.1%		
Second Contact	267	163	62.1%	χ2=7.717, P=0.005	
Third Contact	78	80	49.4%		
Third Contact	78	80	49.4%	χ2=0, P=1	
Fourth Contact	39	40	49.4%		
Fourth Contact	39	40	49.4%	χ2=26.6, P<0.00001	
Fifth Contact	38	1	97.4%		

Comparison of the first contact characteristics between CMD and SMI

In initial contacts, patients with CMD favored government general hospitals (21.7% vs. 7.7%) and private medical practitioners (11.7% vs. 6.0%) compared to SMI patients. SMI individuals were more inclined toward native religious practices (22.1% vs. 14.8%). In the SMI group, 84.9% of first contacts were initiated by relatives or friends, while in the CMD group, patients (44.0%) and their relatives or friends (46.8%) led the first contact. Addiction-related symptoms prompted first contact in 35.2% of CMD cases, while psychiatry-related symptoms played a significant role (51.2%) in the SMI group. Treatment types were generally similar, but SUD medications were more frequently prescribed in the CMD group. For further details, please refer to Table 3 and Figure 1.

Figure 1 Comparison of the contact characteristics between severe mental illness (SMI) and common mental disorder (CMD)

Table 3: Comparison of the first contact characteristics between common mental disorder (CMD) and severe mental illness (SMI)

	CMD	SMI	Statistics (Chi-square/M-W test/K-W test, P)	
Type of first contact (n=589)				
    Public addiction treatment facility	11 (1.9)	15 (2.5)	35.3 (<0.001)	
    Govt. general hospital	63 (10.7)	23 (3.9)		
    Mental health services	19 (3.2)	22 (3.7)		
    Native religious practices	43 (7.3)	66 (11.2)		
    Private medical practitioner	34 (5.8)	18 (3.1)		
    Private psychiatrist/DAC (PvtP)	23 (3.9)	29 (4.9)		
    Integrated care	64 (10.9)	72 (12.2)		
    Others	33 (5.6)	54 (9.2)		
Who initiated the first contact? (n=576)				
    Self	125 (21.7)	24 (4.2)	103.9 (<0.001)	
    Relatives/friends	133 (23.1)	248 (43.1)		
    Others	26 (4.5)	20 (3.5)		
Symptoms leading to first contact (n=505)				
    Psychiatry-related	59 (11.7)	125 (24.8)	80.1 (<0.001)	
    Addiction-related	92 (18.2)	37 (7.3)		
    Mixed	69 (13.7)	79 (15.6)		
    Others	41 (8.1)	3		
Treatment received? Pharmacological vs. Psychosocial vs. Both vs. (n=484)				
    Pharmacological only	189 (39.0)	145 (30.0)	4.9 (p=0.178)	
    Psychosocial only	11 (2.3)	12 (2.5)		
    Both	19 (3.9)	26 (5.4)		
    None	50 (10.3)	32 (6.6)		
Medications for psychiatric disorder received or not (n=162)				
    Received	32 (19.8)	45 (27.8)	13.875 (p<0.001)	
    Not received	60 (37.0)	25 (15.4)		
Medications for SUD received or not (n=162)				
    Received	73 (45.1)	38 (23.5)	11.576 (p=0.001)	
    Not received	19 (11.7)	32 (19.8)		
    The mean time taken for the first visit to integrated services (in months)	34.2 (SD=48.3)	27.4 (SD=37.7)	0.041	

Comparison of the second and third contact characteristics between CMD and SMI

In the subsequent contacts, people with CMD were more likely to continue to seek treatment at government general hospitals; however, treatment seeking for SMI leaned significantly toward integrated care (P < 0.0001). Contact initiation continued to be dominated by the family and relatives of those with SMI. In contrast, the patients and their treating doctors initiated the second and third contacts for those with CMD (P < 0.0001). The symptoms leading to the second and third contacts showed a similar pattern as the first contact (P < 0.001). The patients with SMI were still less likely (P < 0.001) to receive medications for SUD in their second contact with healthcare. The proportion increased in the third contact, but only one in four received it (P = 0.054). Only in the third contact did a significantly more significant (P = 0.005) proportion of patients receive treatment for psychiatric disorders. Please see the Supplementary Tables 3 and 4, and Figure 1 for further details.

Supplementary Table 3: Comparison of the second contact characteristics between Common Mental Disorder (CMD) and Severe Mental Illness (SMI)

Comparison of the second contact characteristics between common mental disorder (CMD) and severe mental illness (SMI)	CMD [n (%)]	SMI [n (%)]	Statistics (Chi-square, P) Fisher’s exact wherever applicable	
Type of second contact (n=430)				
    Govt. general hospital	53 (12.3)	12 (2.8)	38.2, P<0.0001**	
    Mental health services	11 (2.6)	9 (2.1)		
    Private medical practitioner	20 (4.6)	11 (2.6)		
    Integrated care	112 (26.0)	155 (36.0)		
    Others	18 (4.2)	29 (6.7)		
Who initiated the second contact? (n=418)				
    Self	69 (16.5)	20 (4.8)	60.8, P<0.0001**	
    Relatives/Friends	95 (22.7)	170 (40.7)		
    Medical/Mental Health Practitioner	41 (9.8)	15 (3.6)		
    Others	3 (0.7)	5 (1.2)		
Symptoms leading to second contact (n=387)				
    Psychiatry-related	47 (12.1)	120 (31.0)	95.7 (<0.001**)	
    Addiction-related	67 (17.3)	25 (6.5)		
    Mixed	29 (7.5)	55 (14.2)		
    Others	42 (10.8)	2 (0.5)		
Treatment received? Pharmacological vs. Psychosocial vs. Both (n=390)				
    Pharmacological only	151 (38.7)	107 (27.4)	22.2, P<0.001**	
    Psychosocial only	1 (0.25)	2 (0.5)		
    Both	43 (11.0)	86 (22.0)		
Medications for psychiatric disorder received or not (n=192)				
    Received	28 (14.6)	65 (33.8)	2.7, P=0.1	
    Not received	41 (21.3)	58 (30.2)		
Medications for SUD received or not (n=162)				
    Received	59 (30.7)	10 (5.2)	18.0, P<0.0001**	
    Not received	68 (35.4)	55 (28.6)		
**P<.05 is significant

Supplementary Table 4: Comparison of the third contact characteristics between Common Mental Disorder (CMD) and Severe Mental Illness (SMI)

    Comparison of the third contact characteristics between common mental disorder (CMD) and severe mental illness (SMI)	CMD [n (%)]	SMI [n (%)]	Statistics (Chi-square, P), Fisher’s exact wherever applicable	
Type of third contact (n=158)				
    Govt. general hospital	37 (23.4)	4 (2.5)	29.0, P<0.0001	
    Private Medical practitioner	7 (4.4)	3 (1.9)		
    Integrated care	47 (29.7)	31 (19.6)		
    Others	8 (5.1)	21 (13.3)		
Who initiated the third contact? (n=158)				
    Self	37 (23.4)	11 (7)	31.7, P<0.0001	
    Relatives/Friends	22 (13.9)	42 (26.6)		
    Medical/Mental Health Practitioner	40 (25.3)	6 (3.8)		
Symptoms leading to third contact (n=154)				
    Psychiatry-related	12 (7.8)	28 (18.2)	53.7 (<0.001)	
    Addiction-related	41 (26.6)	19 (12.3)		
    Mixed	12 (7.8)	9 (5.8)		
    Others	33 (21.4)	0		
Treatment received? Pharmacological vs. Psychosocial vs. Both (n=146)				
    Pharmacological only	74 (50.7)	32 (22.0)	2.1, P=0.15	
    Psychosocial only	0	3 (2.1)		
    Both	21 (14.4)	16 (10.9)		
Medications for psychiatric disorder received or not (n=56)				
    Received	27 (48.2)	15 (26.8)	7.7, P=0.005	
    Not received	3 (5.3)	11 (19.6)		
Medications for SUD received or not (n=56)				
    Received	17 (30.4)	13 (23.2)	3.7, P=0.054	
    Not received	21	5 (8.9)		

DISCUSSION

To our knowledge, ours might be the first attempt to describe the help-seeking behavior of patients with DD. Our results revealed that one in five persons with DD sought initial help from traditional/religious healers. The percentage was significantly higher for those with SMI than those with CMD. However, in subsequent contacts, help-seeking from traditional healers reduced steeply. Except for the initial contact, integrated DD care comprised the major healthcare contact, ranging from 40% to 80%. A substantial proportion, 1 in 4–6 persons, contacted secondary and emergency public healthcare care. Patients with CMD (vs. SMI) were likely to enroll in general medical and private for-profit healthcare systems. However, private healthcare contributed to 8%–12% of contacts in our study sample. The time lags between the first three contacts were more than 1 year. Although family members initiated help-seeking, we observed a steady increase in self-initiated care contacts and referrals by medical/mental health professionals for subsequent healthcare contacts.

Initial help-seeking from traditional healers reflects cultural practice and social norms. The role of traditional healers in delivering mental healthcare is well-known in Southeast Asia.[29] Complementary and alternative medicine practitioners occupy the vacuum created by the enormous treatment gap in these countries. Although less prevalent in terms of the absolute percentage, the major proportion of our study population chose to consult traditional healers, suggesting they contribute significantly to care pathways in Indian patients with DD, especially those with SMI. Therefore, the mental health policy must aim to integrate traditional practices and medical healthcare. Training, support, and linkage with traditional healers should reduce the time lag between traditional and medical healthcare contacts. A study from Ghana and Nigeria showed that it is feasible to train traditional and faith healers to deliver care for patients with SMI collaboratively; moreover, collaborative care is more effective and cost-effective than traditional models of care.[30]

Integrated DD care not only improves outcomes for mental health and substance use but is also a cost-effective strategy.[31] Evidence suggests the sustainability of integrated treatment programs even after the withdrawal of the research support.[32] Hence, it is encouraging to see integrated DD care as a major healthcare contact in our study population, reflecting these services’ acceptability, appropriateness, and perceived effectiveness. However, integrated DD care requires training, staffing, financing, high fidelity, and agency leadership.[33] Moreover, there is no one-size-fits-all integrated care. This will be different for different mental health conditions (CMD vs. SMI) or substance use and will vary across cultures and contexts.[31] Decision makers and service providers must recognize the challenges and healthcare diversity. We must also allude to the time lags between treatment contacts, which might be attributed to the over-reliance on these specialized integrated services, which are few.

The fact that more than one in six persons in our study sample had physical health comorbidities and persons with DD are more likely to experience violence, self-harm, and other acute emergencies might explain the substantial general medical and emergency contacts.[34] Policymakers must recognize the importance of screening for mental health and substance misuse during these opportunistic encounters. Screening, brief interventions, and linkage with specialized DD services must be introduced to make these health encounters count and provide inclusive support bearing the “no wrong door” philosophy in mind.[35] A progressive increase in medical referrals in our study sample suggests that healthcare professionals recognize the need for linkage with higher and more intensive services.

India still has a traditional collectivistic society, and the family plays a key role as a decision-maker.[36] Therefore, it should not be surprising to see family members’ primary role in initiating healthcare contacts in our study population. Cross-national studies have shown that almost all patients with SMI in India live with their families.[37] The gradual increase in the rates of self-initiated treatment for subsequent contacts indicates that family members could act as a vehicle of change and support and motivate patients to see healthcare contacts. Therefore, the strength of the Indian family structure must be harnessed to reduce the treatment gap for patients with DD.

Persons with DD need access to crisis support, housing, aftercare, interventions to improve treatment retention and reduce substance misuse, and risk assessment and management. These psychosocial interventions may improve the outcome of patients with DD and are recommended as standards of care elsewhere.[38] However, delivering psychosocial interventions will require the availability of adequately trained staff. Limited access to psychosocial interventions in our study sample might reflect limited resources. However, the proportion of people receiving psychosocial interventions increased with further healthcare contacts. Higher contacts indicate a higher severity of DD and higher access to integrated DD care. Hence, these interventions are reserved for those with severe DD, permitting equitable distribution of the strained resources.

In our study, the likelihood of seeking integrated DD treatment had an erratic pattern. It increased significantly between the first and second contact, then plateaued to increase again at the last contact. This pattern reflects a dysfunctional referral and linkage in the healthcare system. The nonavailability of adequate human and other resources for primary and secondary care, a limited organizational mechanism to provide continuity of care, and the nonavailability of health cards are a few reasons for the ineffective healthcare referral system in the country.[39]

We observed similarities and differences compared to the pathways to care for those with SUDs. Like patients with alcohol dependence, those with DD were inclined to seek treatment from specialized treatment centers.[40] Moreover, similar to the treatment-seeking behavior for DD, the patterns of referral and subsequent contacts were also erratic for those with SUDs.[4041] However, patients with SUDs, especially those with opioid dependence had a higher tendency to self-medicate, which is negligible in patients with DD.[27]

Finally, we observed that patients with CMD were more likely to seek SUD treatment, whereas those with SMI were “brought” for mental health symptoms. Interestingly, the providers’ treatment choices aligned with patients’ concerns, unlike the recommended standards of care. While the alignment might indicate patients’ preference and autonomy, treating one disorder will not change the course and outcome of the other disorder. Limited training and capability to screen and treat both conditions might have contributed to the under-treatment.[3] Insufficient treatment might also be explained by the service organization.[42] The negative attitude of the healthcare staff toward SUD treatment and a fear of “abuse” of SUD medications in patients with SMI could be other reasons for exclusion from either CMD or SUD treatment.[43] Delayed integrated care contact in those with CMD might be related to the initial contacts with general medical and private for-profit healthcare. One could attribute the limited awareness of public medical healthcare and financial motives in private care to the delayed time to access integrated care.

Limitation

Our study, conducted in eight centers in India, may only partially represent part of the country due to potential selection bias. Varying participant numbers across centers and a predominantly male sample limit generalizability. The cross-sectional design hinders establishing causation or assessing long-term trajectories. While integrated DD care within existing facilities seems practical, a dedicated DD team is needed. Operational aspects and healthcare providers’ challenges in delivering integrated care have yet to be extensively explored.

CONCLUSION

One in five patients with DD initially seek help from traditional/religious healers, transitioning to integrated care after that. Although family-initiated and supported treatment contacts were common, self-initiated and professional referrals increased over time. General medical and private for-profit healthcare systems are favored by patients with CMD, while private healthcare contributes 8%–12% of contacts. The study underscores the complexities of DD care in India, emphasizing the imperative for standardized, culturally sensitive approaches and collaborative care to effectively address challenges and bridge the treatment gap for those with co-occurring substance use and mental disorders.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Supplementary Figure 1 Center-wise distribution of dual-diagnosis patients

Acknowledgments

We want to acknowledge the center staff who helped in the data collection and logistics.
==== Refs
REFERENCES

1. Alsuhaibani R Smith DC Lowrie R Aljhani S Paudyal V Scope, quality and inclusivity of international clinical guidelines on mental health and substance abuse in relation to dual diagnosis, social and community outcomes: A systematic review BMC Psychiatry 2021 21 209 33892659
2. Obadeji A Oluwole LO Kumolalo BF Dada MU Patterns of substance use disorders and associated co-occurring psychiatric morbidity among patients seen at the psychiatric unit of a tertiary health center Addict Health 2022 14 35 43 35573761
3. Balhara YPS Ghosh A Sarkar S Mahadevan J Pal A Narasimha VL Clinical care of patients with dual disorders in India: Diverse models of care delivery Adv Dual Diagn 2022 15 227 43
4. Ghosh A Sharma N Noble D Basu D Mattoo SK Bn S Predictors of five-year readmission to an inpatient service among patients with alcohol use disorders: Report from a low-middle income country Subst Use Misuse 2022 57 123 33 34668819
5. Subodh BN Hazari N Elwadhi D Basu D Prevalence of dual diagnosis among clinic attending patients in a de-addiction centre of a tertiary care hospital Asian J Psychiatr 2017 25 169 74 28262143
6. Balhara YPS Prakash S Gupta R Pathways to care of alcohol -dependent patients: An exploratory study from a tertiary care substance use disorder treatment center Int J High Risk Behav Addict 2016 5 e30342 27803893
7. Singh S Balhara YPS A review of Indian research on co-occurring cannabis use disorders and psychiatric disorders Indian J Med Res 2017 146 186 95 29265019
8. Basu D Ghosh A Profile of patients with dual diagnosis: Experience from an integrated dual diagnosis clinic in North India J Alcohol Drug Depend 2015 3 2 10
9. Singh S Balhara YP A Review of Indian research on co-occurring psychiatric disorders and alcohol use disorders Indian J Psychol Med 2016 38 10 9 27011396
10. Todd J Green G Harrison M Ikuesan BA Self C Pevalin DJ Social exclusion in clients with comorbid mental health and substance misuse problems Soc Psychiatry Psychiatr Epidemiol 2004 39 581 7 15243697
11. Hunt GE Bergen J Bashir M Medication compliance and comorbid substance abuse in schizophrenia: Impact on community survival 4 years after a relapse Schizophr Res 2002 54 253 64 11950550
12. Ziedonis DM Smelson D Rosenthal RN Batki SL Green AI Henry RJ Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations J Psychiatr Pract 2005 11 315 39 16184072
13. Szerman N Torrens M Maldonado R Balhara YPS Salom C Maremmani I Addictive and other mental disorders: A call for a standardized definition of dual disorders Transl Psychiatry 2022 12 446 36229453
14. Rollins AL Eliacin J Kukla M Wasmuth S Salyers MP McGuire AB Implementation of integrated dual disorder treatment in routine veterans health administration settings Int J Ment Health Addiction 2022 22 112 8
15. Foster G Robertson J Pallis S Segal J The dual diagnosis clinician shared care model – a clinical mental health dual diagnosis integrated treatment initiative Adv Dual Diagn 2022 15 165 76
16. Kikkert M Goudriaan A de Waal M Peen J Dekker J Effectiveness of Integrated Dual Diagnosis Treatment (IDDT) in severe mental illness outpatients with a co-occurring substance use disorder J Subst Abuse Treat 2018 95 35 42 30352668
17. Fantuzzi C Mezzina R Dual diagnosis: A systematic review of the organization of community health services Int J Soc Psychiatry 2020 66 300 10 31957528
18. Gururaj G Varghese M Benegal V Rao GN Pathak K Singh LK National Mental Health Survey of India, 2015–16: Mental Health Systems Bengaluru, Karnataka National Institute of Mental Health and Neuro Sciences NIMHANS Publication No. 130 2016
19. Ambekar A Agrawal A Rao R Mishra AK Khandelwal SK Chadda RK Magnitude of Substance Use in India, Ministry of Social Justice and Empowerment New Delhi, India Government of India 2019
20. Huxley P Krayer A Poole R Gromadzka A Jie DL Nafees S The Goldberg-Huxley model of the pathway to psychiatric care: 21st-century systematic review BJPsych Open 2023 9 e114 doi: 10.1192/bjo. 2023.505 37350326
21. Rogler LH Cortes DE Help-seeking pathways: A unifying concept in mental health care Am J Psychiatry 1993 150 554 61 8465869
22. National Collaborating Centre for Mental Health (UK) Common Mental Health Disorders: Identification and Pathways to Care Leicester (UK) British Psychological Society (UK) 2011
23. Lilford P Wickramaseckara Rajapakshe OB Singh SP A systematic review of care pathways for psychosis in low-and middle-income countries Asian J Psychiatr 2020 54 102237 33271678
24. India State-Level Disease Burden Initiative Mental Disorders Collaborators The burden of mental disorders across the states of India: The Global Burden of Disease Study 1990-2017 Lancet Psychiatry 2020 7 148 61 31879245
25. World Health Organization (WHO) The ICD-10 classification of Mental and Behavioral disorders: Diagnostic Criteria for Research Geneva, Switzerland World Health Organization 1993
26. Gater R de Almeida e Sousa B Barrientos G Caraveo J Chandrashekar CR Dhadphale M The pathways to psychiatric care: A cross-cultural study Psychol Med 1991 21 761 74 1946864
27. Bhad R Gupta R Balhara YPS A study of pathways to care among opioid dependent individuals seeking treatment at a community de-addiction clinic in India J Ethn Subst Abuse 2020 19 490 502 30633657
28. Ghosh A Mahintamani T Somani A Mukherjee D Padhy S Khanra S Exploring help-seeking pathways and disparities in substance use disorder care in India: A multicenter cross-sectional study Indian J Psychiatry 2024 66 528 37 39100378
29. Vijayakumar L The need for mental health research in Southeast Asia Lancet Reg Health Southeast Asia 2023 13 100228 37383552
30. Gureje O Appiah-Poku J Bello T Kola L Araya R Chisholm D Effect of collaborative care between traditional and faith healers and primary health-care workers on psychosis outcomes in Nigeria and Ghana (COSIMPO): A cluster randomised controlled trial Lancet 2020 396 612 22 32861306
31. Rocks S Berntson D Gil-Salmerón A Kadu M Ehrenberg N Stein V Cost and effects of integrated care: A systematic literature review and meta-analysis Eur J Health Econ 2020 21 1211 21 32632820
32. Chokron Garneau H Assefa MT Jo B Ford JH 2nd Saldana L McGovern MP Sustainment of integrated care in addiction treatment settings: Primary outcomes from a cluster-randomized controlled trial Psychiatr Serv 2022 73 280 6 34346729
33. Brunette MF Asher D Whitley R Lutz WJ Wieder BL Jones AM Implementation of integrated dual disorders treatment: A qualitative analysis of facilitators and barriers Psychiatr Serv 2008 59 989 95 18757591
34. Yule AM Kelly JF Integrating treatment for co-occurring mental health conditions Alcohol Res 2019 40 arcr.v40.1.07. doi: 10.35946/arcr.v40.1.07
35. Barbosa C McKnight-Eily LR Grosse SD Bray J Alcohol screening and brief intervention in emergency departments: Review of the impact on healthcare costs and utilization J Subst Abuse Treat 2020 117 108096 32811624
36. Heitzman J Worden RL editors India: A Country Study Washington GPO for the Library of Congress 1995
37. Dani MM Thienhaus OJ Characteristics of patients with schizophrenia in two cities in the U.S. and India Psychiatr Serv 1996 47 300 1 8820556
38. Hakobyan S Vazirian S Lee-Cheong S Krausz M Honer WG Schutz CG Concurrent disorder management guidelines. Systematic Review J Clin Med 2020 9 2406 32731398
39. Godlee F Put patients first and give the money back BMJ 2015 351 h5489 doi: 10.1136/bmj.h5489
40. Pal Singh Balhara Y Prakash S Gupta R Pathways to care of alcohol -dependent patients: An exploratory study from a tertiary care substance use disorder treatment center Int J High Risk Behav Addict 2016 5 e30342 doi: 10.5812/ijhrba. 30342 27803893
41. Somashekar VM John S Praharaj SK Pathways to care in alcohol use disorders: A cross-sectional study from a tertiary hospital in South India J Ethn Subst Abuse 2023 1 14 doi: 10.1080/15332640.2023.2189197
42. Pinderup P Challenges in working with patients with dual diagnosis Adv Dual Diagn 2018 11 60 75
43. Gilchrist G Improving access, assessment and treatment response for substance abusers with co-occurring mental health problems Adv Dual Diagn 2012 5 1 7
